Increased Demand for Ketamine Infusions and Associated Complexities

References

• FinancialNewsMedia.com. Use of ketamine for mental disorders rising while new therapies emerge; 2021. Available from: https://www.prnewswire.com/news-releases/use-of-ketamine-for-mental-disorders-rising-while-new-therapies-emerge-301426549.html. Accessed January 26, 2023.
   Google Scholar
• Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(9):CD011612. PMID: 34510411; PMCID: PMC8434915. doi:10.1002/14651858.CD011612.pub3
   PubMedGoogle Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142. PMID: 23982301; PMCID: PMC3992936. doi:10.1176/appi.ajp.2013.13030392
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. PMID: 16894061. doi:10.1001/archpsyc.63.8.856
   PubMed Web of Science ®Google Scholar
• Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021;33(3):207–228. PMID: 33569971. doi:10.1080/09540261.2020.1854194
   PubMed Web of Science ®Google Scholar
• Jumaili WA, Trivedi C, Chao T, Kubosumi A, Jain S. The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behav Brain Res. 2022;424:113804. PMID: 35181391. doi:10.1016/j.bbr.2022.113804
   Web of Science ®Google Scholar
• Norbury A, Rutter SB, Collins AB, et al. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacol. 2021;46:2266–2277. doi:10.1038/s41386-021-01104-4
   Web of Science ®Google Scholar
• Liriano F, Hatten C, Schwartz TL. Ketamine as treatment for post-traumatic stress disorder: a review. Drugs Context. 2019;8(8):212305.
   Google Scholar
• Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574–1581.
   Web of Science ®Google Scholar
• Ross C, Jain R, Bonnett CJ, Wolfson P. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31(4):271–279.
   Web of Science ®Google Scholar
• Alipoor M, Loripoor M, Kazemi M, Farahbakhsh F, Sarkoohi A. The effect of ketamine on preventing postpartum depression. J Med Life. 2021;14(1):87–92. PMID: 33767791; PMCID: PMC7982256. doi:10.25122/jml-2020-0116
   Google Scholar
• Ma JH, Wang SY, Yu HY, et al. Prophylactic use of ketamine reduces postpartum depression in Chinese women undergoing cesarean section. Psychiatry Res. 2019;279:252–258. PMID: 31147085. doi:10.1016/j.psychres.2019.03.026
   Web of Science ®Google Scholar
• Chen-Li D, Lui LMW, Rosenblat JD, et al. Ketamine as potential treatment for postpartum depression: a narrative review. Ann Clin Psychiatry. 2022;34(4):264–274. PMID: 36282614. doi:10.12788/acp.0082
   Google Scholar
• Li Q, Wang S, Mei X. A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: a meta-analysis. Psychiatry Res. 2022;310:114396. PMID: 35278826. doi:10.1016/j.psychres.2022.114396
   Web of Science ®Google Scholar
• Glue P, Neehoff S, Sabadel A, et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol. 2020;34(3):267–272. PMID: 31526207. doi:10.1177/0269881119874457
   PubMed Web of Science ®Google Scholar
• Tully JL, Dahlén AD, Haggarty CJ, Schiöth HB, Brooks S. Ketamine treatment for refractory anxiety: a systematic review. Br J Clin Pharmacol. 2022;88(10):4412–4426. PMID: 35510346; PMCID: PMC9540337. doi:10.1111/bcp.15374
   Web of Science ®Google Scholar
• Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325–333. PMID: 28849779; PMCID: PMC5729569. doi:10.1038/npp.2017.194
   PubMed Web of Science ®Google Scholar
• Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS Spectr. 2020;25(3):331–342. PMID: 31339086. doi:10.1017/S1092852919001238
   Web of Science ®Google Scholar
• Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72–82. PMID: 29339294. doi:10.1016/j.neuropharm.2018.01.017
   PubMed Web of Science ®Google Scholar
• Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. B J Psych Open. 2021;8(1):e19. PMID: 35048815; PMCID: PMC8715255. doi:10.1192/bjo.2021.1061
   Google Scholar
• Worrell SD, Gould TJ. Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev. 2021;126:573–589. PMID: 33989669. doi:10.1016/j.neubiorev.2021.05.006
   Web of Science ®Google Scholar
• Grabski M, McAndrew A, Lawn W, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152–162. PMID: 35012326. doi:10.1176/appi.ajp.2021.21030277
   PubMed Web of Science ®Google Scholar
• Mills IH, Park GR, Manara AR, Merriman RJ. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM. 1998;91(7):493–503. PMID: 9797933. doi:10.1093/qjmed/91.7.493
   PubMedGoogle Scholar
• Schwartz T, Trunko ME, Feifel D, et al. A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin Case Rep. 2021;9(5):e03869. PMID: 34026123; PMCID: PMC8117825. doi:10.1002/ccr3.3869
   PubMed Web of Science ®Google Scholar
• Ragnhildstveit A, Slayton M, Jackson LK, et al. Ketamine as a novel psychopharmacotherapy for eating disorders: evidence and future directions. Brain Sci. 2022;12(3):382. PMID: 35326338; PMCID: PMC8963252. doi:10.3390/brainsci12030382
   PubMed Web of Science ®Google Scholar
• Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521–546. PMID: 29870458; PMCID: PMC6023575. doi:10.1097/AAP.0000000000000808
   PubMed Web of Science ®Google Scholar
• Orhurhu VJ, Roberts JS, Ly N, Cohen SP. Ketamine in acute and chronic pain management. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 30969646.
   Google Scholar
• Guclu CY. Ketamine for chronic pain. In: Saiz-Sapena N, Granell-Gil M editors. Ketamine Revisited - New Insights into NMDA Inhibitors. IntechOpen; 2022. doi:10.5772/intechopen.104874
   Google Scholar
• Hocking G, Cousins M. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97(6):1730–1739. doi:10.1213/01.ANE.0000086618.28845.9B
   PubMed Web of Science ®Google Scholar
• Yang Y, Maher DP, Cohen SP. Emerging concepts on the use of ketamine for chronic pain. Expert Rev Clin Pharmacol. 2020;13(2):135–146. PMID: 31990596. doi:10.1080/17512433.2020.1717947
   PubMed Web of Science ®Google Scholar
• Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain. 2011;15(3):258–267. PMID: 20638877. doi:10.1016/j.ejpain.2010.06.016
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. doi:10.1001/jamapsychiatry.2017.0080
   PubMed Web of Science ®Google Scholar
• Gautam CS, Mahajan SS, Sharma J, Singh H, Singh J. Repurposing potential of ketamine: opportunities and challenges. Indian J Psychol Med. 2020;42(1):22–29. PMID: 31997862; PMCID: PMC6970308. doi:10.4103/IJPSYM.IJPSYM_228_19
   PubMedGoogle Scholar
• Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370–380. PMID: 23575437; PMCID: PMC6493357. doi:10.1111/cns.12099
   PubMed Web of Science ®Google Scholar
• Hashimoto K. A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clin Psychopharmacol Neurosci. 2012;10(1):59–60. PMID: 23431323; PMCID: PMC3569155. doi:10.9758/cpn.2012.10.1.59
   PubMedGoogle Scholar
• Cook-Sather SD, Adamson PC, Li J, Hakonarson H. CYP2B6*6 or not CYP2B6*6-that remains a question for precision medicine and ketamine! Anesthesiology. 2016;125(6):1085–1087. PMID: 27763886; PMCID: PMC5123751. doi:10.1097/ALN.0000000000001399
   Web of Science ®Google Scholar
• Meshkat S, Rodrigues NB, Di Vincenzo JD, et al. Pharmacogenomics of ketamine: a systematic review. J Psychiatr Res. 2021;145:27–34. PMID: 34844049. doi:10.1016/j.jpsychires.2021.11.036
   Web of Science ®Google Scholar
• Feeney A, Hoeppner BB, Freeman MP, et al. Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID intravenous ketamine study. J Clin Psychiatry. 2022;84(1):22m14491. PMID: 36383742. doi:10.4088/JCP.22m14491
   Google Scholar
• Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–674. PMID: 28067704. doi:10.1213/ANE.0000000000001787
   PubMed Web of Science ®Google Scholar
• Albott CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–e309. PMID: 28394513. doi:10.4088/JCP.16l11277
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Press Release: FDA approves new nasal spray medication for treatment-resistant depression; Available only at a certified doctor’s office or clinic; 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed December 31, 2022.
   Google Scholar
• SPRAVATO® (esketamine) nasal spray [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf. Accessed December 31, 2022.
   Google Scholar
• Macintyre A, Ferris D, Gonçalves B, Quinn N. What has economics got to do with it? The impact of socioeconomic factors on mental health and the case for collective action. Human Soc Sci Commun. 2018;4(1):1–5.
   Google Scholar
• Prego-Domínguez J, Khazaeipour Z, Mallah N, Takkouche B. Socioeconomic status and occurrence of chronic pain: a meta-analysis. Rheumatology. 2021;60(3):1091–1105. PMID: 33276382. doi:10.1093/rheumatology/keaa758
   PubMed Web of Science ®Google Scholar
• Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283–290. PMID: 25886322; PMCID: PMC4258981. doi:10.4103/0259-1162.143110
   PubMedGoogle Scholar
• Grinspoon P. Ketamine for treatment-resistant depression: when and where is it safe? Harvard Health. 2022. Available from: www.health.harvard.edu/blog/ketamine-for-treatment-resistant-depression-when-and-where-is-it-safe-202208092797.
   Google Scholar
• Fortuna A, Schindowski K, Sonvico F. Intranasal drug delivery: challenges and opportunities. Front Pharmacol. 2022;13:868986. PMID: 35308245; PMCID: PMC8924485. doi:10.3389/fphar.2022.868986
   Web of Science ®Google Scholar
• Ulusoy S, Bayar Muluk N, Karpischenko S, et al. Mechanisms and solutions for nasal drug delivery - a narrative review. Eur Rev Med Pharmacol Sci. 2022;26(2Suppl):72–81. PMID: 36524914. doi:10.26355/eurrev_202212_30487
   Google Scholar
• Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 31082131.
   Google Scholar
• Chaves TV, Wilffert B, Sanchez ZM. Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. Am J Drug Alcohol Abuse. 2022:1–10. PMID: 36410032. doi:10.1080/00952990.2022.2132506
   Web of Science ®Google Scholar
• Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218. PMID: 26926127. doi:10.1176/appi.ajp.2015.15081082
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Rutherford C, Keyes KM. Trends in ketamine use, exposures, and seizures in the United States up to 2019. Am J Public Health. 2021;111(11):2046–2049. PMID: 34618543; PMCID: PMC8630483. doi:10.2105/AJPH.2021.306486
   PubMed Web of Science ®Google Scholar
• Landrum RE, Banov MD. The online, at-home ketamine experience: a clinician’s dilemma. Psychiatric Times. 2022;39(10). Available from: https://www.psychiatrictimes.com/view/the-online-at-home-ketamine-experience-a-clinicians-dilemma.
   Google Scholar
• Fitzhenry RI, editor. The Harper Book of Quotations. 3rd ed. New York, NY: Harper; 1993.
   Google Scholar